Day: November 4, 2021

Third Quarter and Recent Highlights:Established Aqua Metals Innovation Center for development of lithium-ion battery recycling solution utilizing proven AquaRefining technologyCompleted third generation Aqualyzer; achieved production over 300% of original modelFinalized definitive agreement to deploy AquaRefining technology in Taiwan to ACME Metal Enterprise Co. and partner to further develop direct to oxide processSigned collaboration agreement with LINICO for clean lithium-ion battery recycling technologyReceived $1.25 million payment from LINICO; non-refundable deposit for the purchase of McCarran Nevada facilityReceived final insurance payment of $5.25 million; achieved a total of $30.25 million collectedFurther advanced discussions with additional potential licenseesRENO, Nev., Nov. 04, 2021 (GLOBE NEWSWIRE)...

-Results from pilot observational analysis demonstrate maintenance of hemoglobin and reduction of total IV iron requirement in adult patients on Triferic receiving chronic hemodialysis-  -Findings align with pivotal trials of Triferic and prior Real World Evidence- WIXOM, Mich., Nov. 04, 2021 (GLOBE NEWSWIRE) — Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today presented new Real World Evidence from a Mid-Sized Dialysis Organization (MDO) pilot observational analysis program at the American Society of Nephrology (ASN) Kidney Week 2021 in San Diego, California. Results indicated that Triferic (Ferric Pyrophosphate Citrate, FPC) is well-tolerated for the replacement of iron to...

  Q3-2021   Key ResultsRevenue (millions) $113.9   • Revenue increased 11% compared to Q3 2020GAAP EPS $0.16   • Generated $7.1 million in operating cash flowNon-GAAP EPS $0.28           PLEASANTON, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and nine months ended September 30, 2021. For the third quarter ended September 30, 2021, the Company reported revenue of $113.9 million, an increase of 10.8% compared to $102.8 million reported for the third quarter of 2020. GAAP gross margin was 59.5% during the third quarter of 2021 compared to 46.2%...

Cloud subscription revenue increased 36% year-over-year to $46.7 millionSubscriptions revenue increased 32% year-over-year to $67.2 million MCLEAN, Va., Nov. 04, 2021 (GLOBE NEWSWIRE) — Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2021. “Appian’s cloud subscription revenue grew 36%, which is above the top end of our guidance. Appian is an ‘engine for change’ that is unifying process mining, workflow, and automation within a single low-code platform. Companies are choosing Appian to adapt quickly to the increasing pace of change,” said Matt Calkins, CEO & Founder. Third Quarter 2021 Financial Highlights:Revenue: Cloud subscription revenue was $46.7 million for the third quarter of 2021, up 36% compared to the third quarter of 2020. Total subscriptions...

TULSA, Okla., Nov. 04, 2021 (GLOBE NEWSWIRE) — AAON, INC. (NASDAQ-AAON), today announced its results for the third quarter of 2021.Financial Highlights: Three Months Ended  September 30,   %     Nine Months Ended  September 30,   %  2021   2020   Change     2021   2020   Change  (in thousands, except share and per share data)     (in thousands, except share and per share data)Net sales $ 138,571     $ 134,772     2.8   %     $ 398,235     $ 397,851     0.1   %Gross profit 36,019     40,848     (11.8 ) %     111,283     121,926     (8.7 ) %Gross profit % 26.0 %   30.3 %         27.9 %   30.6 %    Selling, general and admin. expenses $ 15,897     $ 14,716     8.0   %     $ 47,488     $ 45,869     3.5   %SG&A % 11.5 %   10.9 %         11.9 %   11.5 %    Net income 15,581     20,460     (23.8 ) %     52,572     60,117     (12.6 ) %Net...

Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing Company now operates two GMP manufacturing plants to support rapid clinical advancement of pipeline programs Ended the quarter with $204 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the third quarter of 2021, reporting strong forward momentum in developing its oral vaccine platform consisting of tablet vaccines that it believes may revolutionize public health. During the third quarter, Vaxart started the first Phase II trial of its investigational COVID-19 oral tablet vaccine and dosed its first subjects. Vaxart expects the full data set from this study to be available in Q1 2022. Duke University...

SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Shift Technologies, Inc. (Nasdaq: SFT) and its Board of Directors announced today that Toby Russell will be stepping down as Co-CEO on Feb. 1, 2022. Russell will continue to serve on the company’s Board of Directors and as Strategic Advisor to the company following his transition. George Arison, Co-founder and Co-CEO, will serve as sole CEO, effective Feb. 1, 2022. As of Nov. 4, 2021, the majority of Russell’s day-to-day operational responsibilities are transitioning to Shift’s President, Jeff Clementz, who joined the company on Oct. 1, 2021 after a long career at Walmart and PayPal, and who reports to Arison. “It has been an incredible journey to take Shift from an idea to a publicly traded eCommerce leader,” said Russell. “After leading six straight years of growth, I couldn’t...

NORTHLAKE, Texas, Nov. 04, 2021 (GLOBE NEWSWIRE) — Farmer Bros. Co. (NASDAQ: FARM) (the “Company”) today reported financial results for its first fiscal quarter ended September 30, 2021. First Quarter Fiscal 2022 Highlights:Net sales were $108.4 million, an increase of $11.1 million, or 11.4%, from the prior year period due to continued improvement in the direct-store-delivery (“DSD”) channel compared to the prior year period Gross margin increased to 29.0% from 23.0% in the prior year period Net loss was $2.4 million compared to a net loss of $6.3 million in the prior year period Adjusted EBITDA was $3.5 million compared to $5.7 million in the prior year period* As of September 30, 2021, total debt outstanding was $89.0 million and cash and cash equivalents was $6.0 million(*Adjusted EBITDA, a non-GAAP financial...

Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma Showed 71% ORR and 50% CR; Differentiated Safety Profile with Two Low-Grade Events of CRS and No Events of ICANS or GVHD FT516 Interim Phase 1 Data of 11 Patients in Multi-Dose, Multi-Cycle Escalation Cohorts 2 and 3 for R/R Lymphoma Showed 73% ORR and 55% CR; 63% of Responders Remained in Ongoing Response at Median Time of 5.2 Months; Enrollment in Multiple Disease-specific Expansion Cohorts Initiated FT596 Oral and FT516 Poster Presentations to Highlight Updated Phase 1 Data for R/R Lymphoma at ASH on Monday, December 13; Eight Abstracts Accepted for Presentation SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:...

– Infrastructure: DBM Global maintains backlog of $1.6 billion while converting $383.0 million of revenue in Q3 –– Life Sciences: Glacial Rx® receives milestone FDA approval –– Spectrum: Broadcasting delivers fourth consecutive quarter of profitability – NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) — INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the third quarter ended September 30, 2021. Financial Summary(in millions, except per share amounts) Three Months Ended September 30,   Nine Months Ended September 30,  2021   2020   Increase /(Decrease)   2021   2020   Increase /(Decrease)Revenue $ 394.8       $ 170.5       131.6   %   $ 810.4       $ 538.9       50.4   %Net loss attributable to common stock and participating preferred...